国际标准期刊号: 2161-0681

临床与实验病理学杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 期刊目录
  • 乌尔里希的期刊目录
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Do MRE11 Complex and Steroid Hormone Receptors Expressions Impact the Outcomes in High Grade Serous Ovarian Carcinoma?

Mariana F Gayyed, Nehad Reda Abd El-maqsoud, Medhat Monir Soliman and Ahmed K A Abdel-Hakeem

Background: The prognosis and response of treatment of high grade serous ovarian carcinoma can be predicted by using numbers of biological markers.

Aim: The present study aimed of investigating the clinicopathological significance and prognostic value of MRE11, RAD50, ER and PR expressions in high grade serous ovarian carcinoma. The association between doublestrand breaks repair genes (MRE11-RAD50 complex) and steroid hormones receptor (ER and PR) was also studied.

Methods: An immunohistochemical study was performed on 108 high grade serous ovarian carcinoma cases. The expressions of MRE11, RAD50, ER and PR were evaluated and correlated to patients' clinicopathological data.

Results: The results showed that high MRE11, RAD50, ER and PR protein expressions were seen in 51.9%, 70.4%, 66.7% and 31.5%, of high grade serous ovarian carcinoma cases, respectively. MRE11 and RAD50 overexpression was significantly related to high-stage (p=0.012 and p=0.024, respectively), lymph node metastasis (p=0.002 and p=0.008, respectively), negative estrogen expression (p<0.001 for both) and negative progesterone expression (p<0.001 and p=0.002, respectively). MRE11 and RAD50 overexpression was a poor prognostic factor for OS compared with high ER/PR expression in high grade serous ovarian carcinoma patients.

Conclusion: High immunohistochemical expression of MRE11 and RAD50 in high grade serous ovarian carcinomas is related to poor prognosis.